{"title":"The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.","authors":"Hongjie Xu, Dajun Wei","doi":"10.17305/bb.2024.11103","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor budding has been proposed as a potential prognostic marker in various cancers, but its association with survival outcomes in breast cancer (BC) remains unclear. This meta-analysis aimed to clarify the relationship between tumor budding and survival outcomes in patients with BC. A comprehensive literature search was conducted in PubMed, EMBASE, and Web of Science. Cohort studies examining the association between tumor budding and overall survival (OS) and progression-free survival (PFS) in BC patients were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using a random-effects model to account for potential heterogeneity. Eleven cohort studies, including 2,828 patients, met the inclusion criteria. High tumor budding was significantly associated with poorer OS (HR = 1.89, 95% CI = 1.37-2.60, P < 0.001) and PFS (HR = 1.89, 95% CI = 1.32-2.71, P < 0.001). Subgroup analyses revealed a stronger association in studies where high tumor budding was defined as ≥ 10 buds / high-power field (HPF) compared to those with lower cutoffs. Sensitivity analyses confirmed the robustness of the findings. This meta-analysis demonstrates that high tumor budding is associated with significantly worse OS and PFS in BC patients, underscoring its prognostic significance. These findings suggest tumor budding could be a valuable marker in clinical assessments, and further research is needed to standardize its evaluation criteria in BC.</p>","PeriodicalId":72398,"journal":{"name":"Biomolecules & biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17305/bb.2024.11103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Tumor budding has been proposed as a potential prognostic marker in various cancers, but its association with survival outcomes in breast cancer (BC) remains unclear. This meta-analysis aimed to clarify the relationship between tumor budding and survival outcomes in patients with BC. A comprehensive literature search was conducted in PubMed, EMBASE, and Web of Science. Cohort studies examining the association between tumor budding and overall survival (OS) and progression-free survival (PFS) in BC patients were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using a random-effects model to account for potential heterogeneity. Eleven cohort studies, including 2,828 patients, met the inclusion criteria. High tumor budding was significantly associated with poorer OS (HR = 1.89, 95% CI = 1.37-2.60, P < 0.001) and PFS (HR = 1.89, 95% CI = 1.32-2.71, P < 0.001). Subgroup analyses revealed a stronger association in studies where high tumor budding was defined as ≥ 10 buds / high-power field (HPF) compared to those with lower cutoffs. Sensitivity analyses confirmed the robustness of the findings. This meta-analysis demonstrates that high tumor budding is associated with significantly worse OS and PFS in BC patients, underscoring its prognostic significance. These findings suggest tumor budding could be a valuable marker in clinical assessments, and further research is needed to standardize its evaluation criteria in BC.
肿瘤萌芽被认为是各种癌症的潜在预后标志物,但它与乳腺癌(BC)生存结果的关系仍不清楚。本荟萃分析旨在阐明肿瘤萌芽与乳腺癌患者生存结果之间的关系。我们在 PubMed、EMBASE 和 Web of Science 上进行了全面的文献检索。纳入了研究BC患者肿瘤出芽与总生存期(OS)和无进展生存期(PFS)之间关系的队列研究。采用随机效应模型对危险比(HRs)和95%置信区间(CIs)进行汇总,以考虑潜在的异质性。有11项队列研究符合纳入标准,包括2828名患者。肿瘤高度出芽与较差的OS(HR = 1.89,95% CI = 1.37-2.60,P < 0.001)和PFS(HR = 1.89,95% CI = 1.32-2.71,P < 0.001)显著相关。亚组分析显示,与截值较低的研究相比,将高肿瘤出芽定义为≥10个芽/高倍视野(HPF)的研究具有更强的相关性。敏感性分析证实了研究结果的稳健性。这项荟萃分析表明,肿瘤高发与BC患者较差的OS和PFS相关,突出了其预后意义。这些研究结果表明,肿瘤出芽可能是临床评估中的一个有价值的标志物,需要进一步研究以规范其在 BC 中的评估标准。